The primary focus of my work has been to understand the mechanisms by which cancers subvert normal developmental and stem cell signals to grow, spread and evade therapy. In my effort to develop a full view of the signals that regulate stem cell fate I have used molecular, cellular and genetic approaches and pioneered the development of new tools for visualizing molecular signals in living cells, as well as innovative new methods for high resolution in vivo imaging of cancer growth and progression. Over the last decade our work has ranged from discovery of new signals involved in cancer growth and progression to preclinical work that has formed the basis of clinical trials testing new agents for drug-resistant leukemias. Recently, based on our discoveries, we have partnered with industry to develop new antagonists that could be of broad use in many deadly cancers. I have consistently moved my work in new directions, taken risks and crossed disciplines to explore critical questions in cancer biology, developed innovative strategies to address these questions, and worked to translate these findings to the development of new approaches to target cancer. Our prior studies have collectively set the stage for new avenues of research we will pursue over the course of the next few years. In particular we plan to 1) Use our understanding of the conversion from a benign to malignant phase to develop new interventions that will prevent or block cancer progression, 2) develop new tools to image cancer heterogeneity and identify driver population that may mediate disease relapse, 3) spatially map drug resistant residual disease and develop locoregional targeting strategies and 4) develop and test deliverable molecular sensors for early detection.

Public Health Relevance

The primary focus of my work has been to understand the mechanisms by which cancers subvert normal developmental and stem cell signals to grow, spread and evade therapy. Over the last decade our work has ranged from discovery of new signals involved in cancer growth and progression to preclinical work that has formed the basis of clinical trials testing new agents for drug-resistant leukemias. In the coming years, we will continue to strive to make important contributions that will have a meaningful impact on the many lives that deeply depend on the discoveries we make as a community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
5R35CA197699-04
Application #
9533869
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Woodhouse, Elizabeth
Project Start
2015-08-12
Project End
2022-07-31
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dravis, Christopher; Chung, Chi-Yeh; Lytle, Nikki K et al. (2018) Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity. Cancer Cell 34:466-482.e6
Todoric, Jelena; Antonucci, Laura; Di Caro, Giuseppe et al. (2017) Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell 32:824-839.e8
Hui, Sheng; Ghergurovich, Jonathan M; Morscher, Raphael J et al. (2017) Glucose feeds the TCA cycle via circulating lactate. Nature 551:115-118
Bajaj, Jeevisha; Konuma, Takaaki; Lytle, Nikki K et al. (2016) CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. Cancer Cell 30:792-805
Fox, Raymond G; Lytle, Nikki K; Jaquish, Dawn V et al. (2016) Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature 534:407-411
Koechlein, Claire S; Harris, Jeffrey R; Lee, Timothy K et al. (2016) High-resolution imaging and computational analysis of haematopoietic cell dynamics in vivo. Nat Commun 7:12169